Myrexis, Inc.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.myrexis.com
Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Myrexis Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT01285414
- Locations
- πΊπΈ
Stanford University, Stanford, California, United States
πΊπΈUniversity of Texas Health Science Center at Houston, Houston, Texas, United States
A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days
- First Posted Date
- 2010-04-01
- Last Posted Date
- 2010-04-01
- Lead Sponsor
- Myrexis Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT01097070
- Locations
- πΊπΈ
Quest Clinical Research, San Francisco, California, United States
πΊπΈGary J. Richmond, MD, PA, Ft. Lauderdale, Florida, United States
πΊπΈAIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy
- Conditions
- HIV Infections
- Interventions
- Drug: MPC-4326 plus a 2-3 drug optimized background regimen (OBR)Drug: 3-4 commercially available antiretroviral drugs
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2010-06-14
- Lead Sponsor
- Myrexis Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT01026727
- Locations
- πΊπΈ
AIDS Healthcare Foundation Research Center, Beverly Hills, California, United States
πΊπΈPeter Wolfe, MD, PC, Los Angeles, California, United States
πΊπΈQuest Clinical Research, San Francisco, California, United States
Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection.
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2010-01-06
- Lead Sponsor
- Myrexis Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00967187
- Locations
- π¦πΊ
AIDS Research Initiative, Darlinghurst, New South Wales, Australia
π¦πΊHoldsworth House Medical Practice, Darlinghurst, New South Wales, Australia
π¦πΊSt Vincent's Hospital, Darlinghurst, New South Wales, Australia
Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments
- Conditions
- Cancer
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2011-10-14
- Lead Sponsor
- Myrexis Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT00920205
- Locations
- πΊπΈ
Nevada Cancer Institute, Las Vegas, Nevada, United States
πΊπΈFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
πΊπΈSouth Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme
- Conditions
- Glioblastoma Multiforme
- First Posted Date
- 2009-05-05
- Last Posted Date
- 2011-10-14
- Lead Sponsor
- Myrexis Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00892931
- Locations
- πΊπΈ
Barrow Neurological Institute, Phoenix, Arizona, United States
πΊπΈCedars-Sinai Medical Center, Los Angeles, California, United States
πΊπΈStanford University, Stanford, California, United States
Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme
- Conditions
- Glioblastoma Multiforme
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2011-03-25
- Lead Sponsor
- Myrexis Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00635557
- Locations
- πΊπΈ
The Angeles Clinic and Research Institute, Los Angeles, California, United States
πΊπΈEmory University, Atlanta, Georgia, United States
πΊπΈMt. Sinai School of Medicine, New York, New York, United States
Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma
- Conditions
- Metastatic Melanoma
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2010-08-23
- Lead Sponsor
- Myrexis Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT00609011
- Locations
- πΊπΈ
The Angeles Clinic, Los Angeles, California, United States
πΊπΈCancer Centers of Florida, Ocoee, Florida, United States
πΊπΈCancer Centers of the Carolinas, Greenville, South Carolina, United States
Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*
- First Posted Date
- 2007-08-03
- Last Posted Date
- 2010-01-20
- Lead Sponsor
- Myrexis Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT00511368
- Locations
- πΊπΈ
UCLA Medical Center, Los Angeles, California, United States
πΊπΈQuest Clinical Research, San Francisco, California, United States
πΊπΈUniversity of Colorado Health Science Center, Denver, Colorado, United States
Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors
- Conditions
- Refractory Solid Tumors
- First Posted Date
- 2006-11-01
- Last Posted Date
- 2008-02-13
- Lead Sponsor
- Myrexis Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00394446
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
πΊπΈHuntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States